Shuttle Pharmaceuticals, Inc.

UEI
DRXGHKX67C67
CAGE
6YHD8
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Subchapter S Corporation
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
SAM.gov registration date

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Shuttle Pharmaceuticals, Inc.'s 5 most recent federal contract and grant awards, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
Topic 345: predictive biomarkers of prostate cancer patient sensitivity for radiation late effects Contract · 75N91019C00031 National Cancer Institute $1,903,095
Topic 352: cell-based models for prostate cancer health disparity research- moonshot project (phase II) Contract · 75N91018C00016 National Cancer Institute $1,484,350
Sbir phase i topic 352 cell-based models for prostate cancer health disparity research Contract · HHSN261201600038C National Cancer Institute $224,687
Predictive biomarkers of prostate cancer patient sensitivity for radiation late effects Contract · HHSN261201600027C National Cancer Institute $299,502
R & d- medical: biomedical (basic research) Contract · HHSN261201400013C National Cancer Institute $1,560,780

Quick answers

What is Shuttle Pharmaceuticals, Inc.'s UEI?

Shuttle Pharmaceuticals, Inc.'s Unique Entity ID (UEI) in SAM.gov is DRXGHKX67C67.

What is Shuttle Pharmaceuticals, Inc.'s CAGE code?

Shuttle Pharmaceuticals, Inc.'s CAGE code is 6YHD8.

What is Shuttle Pharmaceuticals, Inc.'s primary NAICS code?

Shuttle Pharmaceuticals, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Is Shuttle Pharmaceuticals, Inc. registered in SAM.gov?

Shuttle Pharmaceuticals, Inc.'s SAM.gov registration expired on July 9, 2025.

What is Shuttle Pharmaceuticals, Inc.'s most recent federal award?

Shuttle Pharmaceuticals, Inc.'s most recent federal contract award is Topic 345: predictive biomarkers of prostate cancer patient sensitivity for radiation late effects (75N91019C00031), from National Cancer Institute, on September 9, 2019.

On GovTribe

See Shuttle Pharmaceuticals, Inc.'s full federal record

  • Federal contract awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login